<DOC>
	<DOCNO>NCT00609388</DOCNO>
	<brief_summary>The evaluation efficacy intraportal infusion Tacrolimus , time liver graft implantation , compare control group without immunosuppressive intraportal infusion ( Placebo : Saline solution 0.9 % ) respect initial liver function measure parameter liver function ( LFP ) : AST ( U/L ) , ALT ( U/L ) , total Bilirubin ( mg/dL ) coagulation factor : NT ( % ) , PTT ( ) , INR .</brief_summary>
	<brief_title>Tacrolimus During Implantation Effect Ischemia-reperfusion Injury Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Multi organ transplantation retransplantation ABO incompatible donor organ recipient Patients , list liver transplantwaiting list Vienna General Hospital fulfill clinical requirement ( local allocation ) Written informed consent Age &gt; 18 First transplantation Fulminant failure liver LiverLiving donor recipient pregnant nursing woman Allergy/Intolerance antimetabolite , HCO60 , EL Cremophor similar compound , Steroids macrolide antibiotic HIVpositive donor recipients Participants another clinical study Patient form substance abuse , psychiatric disorder condition , , opinion investigator , may invalidate communication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>